In today’s recent session, 1.34 million shares of the Insight Molecular Diagnostics Inc (NASDAQ:IMDX) have been traded, and its beta is 0.99. Most recently the company’s share price was $2.82, and it changed around -$0.38 or -11.88% from the last close, which brings the market valuation of the company to $80.65M. IMDX at last check was trading at a discount to its 52-week high of $4.75, offering almost -68.44% off that amount. The share price’s 52-week low was $1.92, which indicates that the recent value has risen by an impressive 31.91% since then.

Insight Molecular Diagnostics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 2 recommended IMDX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.

Insight Molecular Diagnostics Inc (NASDAQ:IMDX) trade information

Instantly IMDX has been showing red trend so far today with a performance of -11.88% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 18.49% year-to-date, but still up 6.82% over the last five days. On the other hand, Insight Molecular Diagnostics Inc (NASDAQ:IMDX) is 0.71% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 64.75% from its current value. Analyst projections state that IMDX is forecast to be at a low of $8 and a high of $8.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.82%. Insight Molecular Diagnostics Inc earnings are expected to increase by 79.61% in 2025, but the outlook is positive 43.74% per year for the next five years.

IMDX Dividends

Insight Molecular Diagnostics Inc’s next quarterly earnings report is expected to be released in July.